A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

Ryan Mattison, Alcee Jumonville, Patrick James Flynn, Alvaro Moreno Aspitia, Charles Erlichman, Betsy Laplant, Mark B. Juckett

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) not fit for intensive treatment need novel therapy options. Vascular endothelial growth factor (VEGF) receptor inhibition is one potential mechanism by which AML and MDS could be treated. The receptor tyrosine kinase inhibitor AZD2171 (cediranib) has activity against VEGF receptors KDR and FLT-1. This multicenter phase II study was designed to test cediranib's activity in patients with AML or high-risk MDS. The primary endpoint was confirmed disease response defined as a composite of complete remission, partial remission or hematologic improvement. The study enrolled 23 subjects in the AML cohort and 16 subjects in the MDS cohort. There were no confirmed responses in either group. Since the study met the stopping rule after the first stage of enrollment, the trial was closed to further accrual. Common adverse events in both cohorts included thrombocytopenia, neutropenia, anemia, fatigue, dyspnea, diarrhea, nausea and dehydration.

Original languageEnglish (US)
Pages (from-to)2061-2066
Number of pages6
JournalLeukemia and Lymphoma
Volume56
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Myelodysplastic Syndromes
Acute Myeloid Leukemia
Vascular Endothelial Growth Factor Receptor
Receptor Protein-Tyrosine Kinases
Therapeutics
Neutropenia
Dehydration
Thrombocytopenia
Dyspnea
Nausea
Fatigue
Anemia
Diarrhea
cediranib

Keywords

  • Myeloid leukemias and dysplasias
  • Pharmacotherapeutics
  • Signal transduction

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. / Mattison, Ryan; Jumonville, Alcee; Flynn, Patrick James; Moreno Aspitia, Alvaro; Erlichman, Charles; Laplant, Betsy; Juckett, Mark B.

In: Leukemia and Lymphoma, Vol. 56, No. 7, 01.07.2015, p. 2061-2066.

Research output: Contribution to journalArticle

Mattison, Ryan ; Jumonville, Alcee ; Flynn, Patrick James ; Moreno Aspitia, Alvaro ; Erlichman, Charles ; Laplant, Betsy ; Juckett, Mark B. / A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 7. pp. 2061-2066.
@article{4d42158a38ff4794a9283d4d6e071c17,
title = "A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome",
abstract = "Patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) not fit for intensive treatment need novel therapy options. Vascular endothelial growth factor (VEGF) receptor inhibition is one potential mechanism by which AML and MDS could be treated. The receptor tyrosine kinase inhibitor AZD2171 (cediranib) has activity against VEGF receptors KDR and FLT-1. This multicenter phase II study was designed to test cediranib's activity in patients with AML or high-risk MDS. The primary endpoint was confirmed disease response defined as a composite of complete remission, partial remission or hematologic improvement. The study enrolled 23 subjects in the AML cohort and 16 subjects in the MDS cohort. There were no confirmed responses in either group. Since the study met the stopping rule after the first stage of enrollment, the trial was closed to further accrual. Common adverse events in both cohorts included thrombocytopenia, neutropenia, anemia, fatigue, dyspnea, diarrhea, nausea and dehydration.",
keywords = "Myeloid leukemias and dysplasias, Pharmacotherapeutics, Signal transduction",
author = "Ryan Mattison and Alcee Jumonville and Flynn, {Patrick James} and {Moreno Aspitia}, Alvaro and Charles Erlichman and Betsy Laplant and Juckett, {Mark B.}",
year = "2015",
month = "7",
day = "1",
doi = "10.3109/10428194.2014.977886",
language = "English (US)",
volume = "56",
pages = "2061--2066",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

AU - Mattison, Ryan

AU - Jumonville, Alcee

AU - Flynn, Patrick James

AU - Moreno Aspitia, Alvaro

AU - Erlichman, Charles

AU - Laplant, Betsy

AU - Juckett, Mark B.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) not fit for intensive treatment need novel therapy options. Vascular endothelial growth factor (VEGF) receptor inhibition is one potential mechanism by which AML and MDS could be treated. The receptor tyrosine kinase inhibitor AZD2171 (cediranib) has activity against VEGF receptors KDR and FLT-1. This multicenter phase II study was designed to test cediranib's activity in patients with AML or high-risk MDS. The primary endpoint was confirmed disease response defined as a composite of complete remission, partial remission or hematologic improvement. The study enrolled 23 subjects in the AML cohort and 16 subjects in the MDS cohort. There were no confirmed responses in either group. Since the study met the stopping rule after the first stage of enrollment, the trial was closed to further accrual. Common adverse events in both cohorts included thrombocytopenia, neutropenia, anemia, fatigue, dyspnea, diarrhea, nausea and dehydration.

AB - Patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) not fit for intensive treatment need novel therapy options. Vascular endothelial growth factor (VEGF) receptor inhibition is one potential mechanism by which AML and MDS could be treated. The receptor tyrosine kinase inhibitor AZD2171 (cediranib) has activity against VEGF receptors KDR and FLT-1. This multicenter phase II study was designed to test cediranib's activity in patients with AML or high-risk MDS. The primary endpoint was confirmed disease response defined as a composite of complete remission, partial remission or hematologic improvement. The study enrolled 23 subjects in the AML cohort and 16 subjects in the MDS cohort. There were no confirmed responses in either group. Since the study met the stopping rule after the first stage of enrollment, the trial was closed to further accrual. Common adverse events in both cohorts included thrombocytopenia, neutropenia, anemia, fatigue, dyspnea, diarrhea, nausea and dehydration.

KW - Myeloid leukemias and dysplasias

KW - Pharmacotherapeutics

KW - Signal transduction

UR - http://www.scopus.com/inward/record.url?scp=84938089200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938089200&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.977886

DO - 10.3109/10428194.2014.977886

M3 - Article

C2 - 25329007

AN - SCOPUS:84938089200

VL - 56

SP - 2061

EP - 2066

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -